Colossal Biosciences has launched its latest AI platform, GenoMorph, to aid in the ambitious goal of de-extinction. The technology uses advanced 3D morphology and comparative genomics to identify key genetic changes, even with limited data, as demonstrated in their work with the dodo bird. Unlike their better-preserved woolly mammoth project, the dodo’s one available genome poses a significant challenge, prompting the development of this innovative 'treasure map' approach.

By comparing developmental data from various birds, GenoMorph helps predict genetic changes that could mimic the dodo’s iconic appearance. The company is also developing a new gene-editing delivery system using lipid nanoparticles, enabling faster and more precise testing of edits in bird embryos, bypassing the lengthy breeding cycles.

In a sign of growing support, XPRIZE founder Peter Diamandis has invested in Colossal and launched a new VC firm, NeoGenesis Capital, to back similar projects. However, the ethical implications of such technologies remain a contentious topic, with scientists emphasizing the need for rigorous testing and validation to ensure safety and effectiveness.

The success of GenoMorph in the dodo project could mark a turning point in de-extinction efforts, but it also raises questions about the long-term consequences of tampering with extinct species’ genetic codes. As Colossal Biosciences continues to refine its approach, the broader question of whether such technologies are beneficial or harmful remains to be answered.